Shenzhen Salubris Pharmaceuticals
CompanyChina
Shenzhen Salubris Pharmaceuticals develops one asset, in phase 2 (SAL003 in hypercholesterolemia and mixed dyslipidemia). Mostly antibody acting on lipid and ceramide metabolism and PCSK9; based in China.
- 1
- Asset
- Furthest stage
- Phase 2
- 7
- Trials
- 0
- Signals
Pipeline
1PCSK9 inhibitor antibody evaluated in combination with atorvastatin for dyslipidemia
Phase 2, Antibody, Lipid and ceramide metabolism, PCSK9, hypercholesterolemia and mixed dyslipidemia
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials7
- Signals1
- Similar companies6